{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:20:01Z","timestamp":1786119601439,"version":"build-2736575974"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,12,15]]},"DOI":"10.1097\/qai.0b013e3181f6d916","type":"journal-article","created":{"date-parts":[[2010,10,2]],"date-time":"2010-10-02T06:47:06Z","timestamp":1286002026000},"page":"597-605","source":"Crossref","is-referenced-by-count":24,"title":["Sustained Long-Term Antiviral Maintenance Therapy in HCV\/HIV-Coinfected Patients (SLAM-C)"],"prefix":"10.1097","volume":"55","author":[{"given":"Kenneth E","family":"Sherman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet W","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeel A","family":"Butt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Triin","family":"Umbleja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beverly","family":"Alston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret J","family":"Koziel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion G","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Sulkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary D","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond T","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-9-20210131","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1002\/hep.21722","article-title":"HIV and liver disease forum: conference proceedings.","volume":"45","author":"Sherman","year":"2007","journal-title":"Hepatology"},{"key":"R2-9-20210131","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1002\/hep.510300409","article-title":"Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group.","volume":"30","author":"Benhamou","year":"1999","journal-title":"Hepatology"},{"key":"R3-9-20210131","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1053\/jhep.2001.29201","article-title":"The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study.","volume":"34","author":"Di Martino","year":"2001","journal-title":"Hepatology"},{"key":"R4-9-20210131","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1136\/gut.52.7.1035","article-title":"Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients.","volume":"52","author":"Mohsen","year":"2003","journal-title":"Gut"},{"key":"R5-9-20210131","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1086\/318501","article-title":"Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection.","volume":"32","author":"Bica","year":"2001","journal-title":"Clin Infect Dis"},{"key":"R6-9-20210131","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.jhep.2005.01.022","article-title":"Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol.","volume":"42","author":"Salmon-Ceron","year":"2005","journal-title":"J Hepatol"},{"key":"R7-9-20210131","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1001\/archinte.166.15.1632","article-title":"Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study.","volume":"166","author":"Weber","year":"2006","journal-title":"Arch Intern Med"},{"key":"R8-9-20210131","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1365-2516.2006.01322.x","article-title":"Percutaneous liver biopsy in adult haemophiliacs with hepatitis C virus: safety of outpatient procedure and impact of human immunodeficiency virus coinfection on the spectrum of liver disease.","volume":"13","author":"Sterling","year":"2007","journal-title":"Haemophilia"},{"key":"R9-9-20210131","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1365-2893.2006.00824.x","article-title":"Response rates to pegylated interferon and ribavirin in HCV\/HIV coinfection: a research synthesis.","volume":"14","author":"Shire","year":"2007","journal-title":"J Viral Hepat"},{"key":"R10-9-20210131","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/1097-0215(20000901)87:5<741::AID-IJC18>3.0.CO;2-B","article-title":"Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients.","volume":"87","author":"Tanaka","year":"2000","journal-title":"Int J Cancer"},{"key":"R11-9-20210131","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1136\/gut.48.6.843","article-title":"Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis.","volume":"48","author":"Gramenzi","year":"2001","journal-title":"Gut"},{"key":"R12-9-20210131","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0168-8278(96)80022-5","article-title":"Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis.","volume":"24","author":"Mazzella","year":"1996","journal-title":"J Hepatol"},{"key":"R13-9-20210131","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0016-5085(99)70402-6","article-title":"A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia.","volume":"117","author":"Shiffman","year":"1999","journal-title":"Gastroenterology"},{"key":"R14-9-20210131","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1742-6405-4-11","article-title":"Predictors of disease progression in HIV infection: a review.","volume":"4","author":"Langford","year":"2007","journal-title":"AIDS Res Ther"},{"key":"R15-9-20210131","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11894-002-0034-y","article-title":"Treatment of chronic hepatitis C with PEGylated interferon and ribavirin.","volume":"4","author":"Cornberg","year":"2002","journal-title":"Curr Gastroenterol Rep"},{"key":"R16-9-20210131","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1056\/NEJMoa0707615","article-title":"Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon.","volume":"359","author":"Di Bisceglie","year":"2008","journal-title":"N Engl J Med"},{"key":"R18-9-20210131","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.cgh.2006.10.016","article-title":"Effect of prolonged interferon therapy on the outcome of hepatitis C virus-related cirrhosis: a randomized trial.","volume":"5","author":"Fartoux","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R19-9-20210131","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1097\/QAD.0b013e32830e6d51","article-title":"Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis.","volume":"22","author":"Thein","year":"2008","journal-title":"AIDS"},{"key":"R20-9-20210131","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1053\/jhep.2001.26517","article-title":"Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy.","volume":"34","author":"Benhamou","year":"2001","journal-title":"Hepatology"},{"key":"R21-9-20210131","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jhep.2005.07.006","article-title":"Slower fibrosis progression in HIV\/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy.","volume":"44","author":"Brau","year":"2006","journal-title":"J Hepatol"},{"key":"R22-9-20210131","first-page":"144","article-title":"Transient elastography discloses identical distribution of liver fibrosis in chronic hepatitis C between HIV-negative and HIV-positive patients on HAART.","volume":"139-","author":"Grunhage","year":"15","journal-title":"Eur J Med Res"},{"key":"R23-9-20210131","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.1086\/383151","article-title":"Nucleoside analogues and mitochondrial toxicity.","volume":"38","author":"Fleischer","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"23","key":"R24-9-20210131","first-page":"2839","article-title":"Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. Jama.","volume":"292","author":"Carrat","year":"2004","journal-title":"December"},{"issue":"5","key":"R25-9-20210131","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1056\/NEJMoa032653","article-title":"Peginterferon alpha-2a plus ribavirin versus interferon alpha-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons.","volume":"351","author":"Chung","year":"2004","journal-title":"New England Journal of Medicine"},{"key":"R26-9-20210131","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa040842","article-title":"Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.","volume":"351","author":"Torriani","year":"2004","journal-title":"N Engl J Med"},{"key":"R27-9-20210131","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1089\/aid.2007.0011","article-title":"Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial.","volume":"23","author":"Nunez","year":"2007","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R28-9-20210131","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1053\/j.gastro.2006.06.008","article-title":"Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1.","volume":"131","author":"Conjeevaram","year":"2006","journal-title":"Gastroenterology"},{"key":"R29-9-20210131","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1002\/hep.20212","article-title":"Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1.","volume":"39","author":"Jeffers","year":"2004","journal-title":"Hepatology"},{"key":"R30-9-20210131","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1056\/NEJMoa032502","article-title":"Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites.","volume":"350","author":"Muir","year":"2004","journal-title":"N Engl J Med"},{"key":"R31-9-20210131","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature08309","article-title":"Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.","volume":"461","author":"Ge","year":"2009","journal-title":"Nature"},{"key":"R32-9-20210131","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nature08463","article-title":"Genetic variation in IL28B and spontaneous clearance of hepatitis C virus.","volume":"461","author":"Thomas","year":"2009","journal-title":"Nature"}],"container-title":["JAIDS Journal of Acquired Immune Deficiency Syndromes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/QAI.0b013e3181f6d916","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:41:18Z","timestamp":1786041678000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00126334-201012150-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12,15]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/qai.0b013e3181f6d916","relation":{},"ISSN":["1525-4135"],"issn-type":[{"value":"1525-4135","type":"print"}],"subject":[],"published":{"date-parts":[[2010,12,15]]}}}